WO2000041697A1 - Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale - Google Patents

Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale Download PDF

Info

Publication number
WO2000041697A1
WO2000041697A1 PCT/EP1999/010275 EP9910275W WO0041697A1 WO 2000041697 A1 WO2000041697 A1 WO 2000041697A1 EP 9910275 W EP9910275 W EP 9910275W WO 0041697 A1 WO0041697 A1 WO 0041697A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
branched
unbranched
substituted
mmol
Prior art date
Application number
PCT/EP1999/010275
Other languages
German (de)
English (en)
Inventor
Gerd Steiner
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Francisco Javier Garcia-Ladona
Hans-Peter Hofmann
Liliane Unger
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL14414599A priority Critical patent/IL144145A0/xx
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Priority to JP2000593308A priority patent/JP2002534467A/ja
Priority to CA002359390A priority patent/CA2359390A1/fr
Priority to AU22851/00A priority patent/AU2285100A/en
Priority to BR9916888-0A priority patent/BR9916888A/pt
Priority to MXPA01006966A priority patent/MXPA01006966A/es
Priority to SK968-2001A priority patent/SK9682001A3/sk
Priority to PL99348916A priority patent/PL348916A1/xx
Priority to EP99966990A priority patent/EP1140099A1/fr
Priority to KR1020017008690A priority patent/KR20010101440A/ko
Publication of WO2000041697A1 publication Critical patent/WO2000041697A1/fr
Priority to BG105688A priority patent/BG105688A/xx
Priority to NO20013408A priority patent/NO20013408L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to the use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia
  • R 1 for hydrogen, (C ⁇ _ 6 ) Al yl branched or unbranched, CO- (C ⁇ _ 4 ) alkyl, C0 2 tBu, CO-aryl and a phenylalkyl- C 1 -C 4 -R.es, which in turn on the aromatic F, Cl, Br, I, 5 1 -C alkyl, C 1 -C 4 alkoxy, trifluoroethyl, hydroxy, amino, cyano or nitro may be substituted,
  • A is branched or unbranched (C ⁇ - ⁇ o) -alkylene or straight-chain or branched (C2 10) -alkylene which 0 comprises at least one group Z which is selected from 0, S, MR2, cyclopropyl, CHOH, a double or a triple bond,
  • R 2 represents hydrogen and C 1 -C 4 alkyl, 5
  • B stands for 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and 0
  • Ar for phenyl which may be branched or unbranched by (C ⁇ _ 6 ) alkyl, O- (C ⁇ _ 6 ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 2 2 , C0 2 R 2 , cyano or substituted phenyl, tetralin, indane, more highly condensed 5 aromatics such as naphthalene, which is optionally substituted by (C ⁇ ) alkyl or 0 (C ⁇ -) alkyl, anthracene or 5- or 6-membered aromatic heterocycles with 1 to 2 hetero - ato en, which are independently selected from O and N, which can be fused with other aromatic radicals.
  • A, X and Y have the meaning given above and Q represents a cleavable group (for example Cl, Br, I, alkanesulfonyloxy or arylsulfonyloxy), with a compound of the formula III,
  • B 1 is piperazine or homopiperazine and W is hydrogen or one of the usual amino protecting groups (such as Boc or Cbz), with a compound of general formula VIII
  • P is B (OH) 2 , SnR 3 , OTf, Br, Cl, or I and R is iC 4 -Al yl, in a known manner; or
  • B2 is 4-tetrahydro-l, 2, 3, 6-pyridine and the corresponding ring compounds enlarged by a methylene group and Pi is Cl, Br, I, SnR 3 - where R is C 1 -C 4 -alkyl, OTf with a compound of the general formula X
  • B 3 represents piperidines linked in the 1,4-position and the corresponding ring compounds enlarged by a methylene group
  • the hydrochloride was precipitated from the solution of the residue in ethyl acetate by adding 30% isopropanol / HCl solution, which was dried in a vacuum drying cabinet at 40 ° C. after suction. 17 g (67%) of substance were obtained. Mp ..- 200 ° C.
  • the aqueous phase was filtered, made alkaline and extracted with dichloromethane. After drying over sodium sulfate and extensive removal of the solvent, the mixture was diluted with diethyl ether and the hydrochloride was precipitated with ethereal hydrochloric acid. 3.2 g (67%) of the product were obtained. (Mp: 293 ° C).
  • R 1 , R 2 independently of one another represent (C ⁇ - ⁇ ) alkyl
  • R 3 , R 4 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, OH, 0- (C ⁇ - 6 ) alkyl branched or unbranched, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0 2 R 7 , nitro, cyano, pyrrole, for a phenylalkyl C 1 -C 4 radical, which in turn is aromatic on F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl , Hydroxy, amino, cyano or nitro can be substituted,
  • R 5 , R 6 independently of one another for hydrogen, (C ⁇ - 6 ) alkyl branched or unbranched, COPh, C0 2 tBu, CO- (C ⁇ _ 4 ) alkyl or together for a 5- or 6-membered ring which may optionally be a second N contains (e.g. piperazine),
  • R 7 represents hydrogen and (C ⁇ _g) alkyl branched or unbranched
  • A represents branched or unbranched (C ⁇ _ ⁇ o) alkylene or straight-chain or branched (C_ ⁇ o) alkylene which comprises at least one group Z which is selected from 0, S, NR 7 , cyclopropyl, CHOH, a double or a triple bond,
  • B represents 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and
  • Ar for phenyl which is optionally branched or unbranched by (Ci- ⁇ ) alkyl, 0- (Ci- ⁇ ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0 2 R 7, cyano or phenyl, tetralin, indan, highly condensed aromatics such as naphthalene, which is optionally substituted by (C 1 - 4) alkyl or 0 (C ⁇ _ 4) is substituted alkyl, anthracene or 5- or 6-membered aromatic heterocycles having 1 up to 2 heteroatoms, which are independently selected from 0 and N, and those with others aromatic residues can be fused, for example quinoline, isoquinoline, phthalazine, indole and quinazoline, which in turn can be substituted with phenyl,
  • R 1 to R 4 and A have the meaning given above and Q represents a cleavable group (for example Cl, Br, I, alkanesulfonyloxy or arylsulfonyloxy), with a secondary amine of the formula III,
  • B 1 is piperazine or homopiperazine and W is hydrogen or one of the usual amino protecting groups (such as Boc or Cbz), with a compound of general formula VIII
  • P is B (OH) 2 , SnR 3 , OTf, Br, Cl, or I and R is C 1 -C 4 -alkyl, in a known manner; or
  • B 3 represents piperidines linked in the 1,4-position and the corresponding ring compounds enlarged by a methylene group;
  • Example 2 3, 3-Dimethyl-2- [3- (4- (2-phenylquinazoline-4-yl) piperazin-1-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole-1,1-dioxide (mp: 269 ° C., hydrochloride).
  • Example 3 3, 3-Dimethyl-2- [3- (4-quinolin-2-yl-piperazine-l-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 63 ° C).
  • Example 4 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-l, 4-diazapan-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, 1-dioxide (mp: 126 ° C, hydrochloride).
  • Example 5 3,3-dimethyl-2- [3- (4- (4-chlorophthalazin-l-yl) piperazin-1-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 190 ° C.).
  • Example 6 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) -2-methylene prop-l-yl] -2, 3-dihydro-1,2 -benzisothiazole-l, l-dioxide (mp: 193 ° C).
  • Example 7 3, 3-Dimethyl-2- [2- (4-quinazolin-4-yl-piperazine-1-yl) eth-1-yl] -2, 3-dihydro-1, 2-benzisothiazole- l, 1-dioxide (mp: 178 ° C, hydrochloride).
  • Example 8 3, 3-Dimethyl-2- [2- (4-naphth-l-yl-piperazine-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 282 ° C, hydrochloride).
  • Example 9 3, 3-Dimethyl-2- [2- (4-isoquinolin-4-yl) piperazin-1-yl) eth-l-yl] -2, 3-dihydro-l, 2-benziso - thiazole-1,1-dioxide (mp: 243 ° C, hydrochloride).
  • Example 10 3,3-Diethyl-2- [2- (4-naphth-l-yl-piperazine-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (oil).
  • Example 11 3,3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-1-yl] -6-pyrrole-l-yl-2,3- dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 269 ° C., hydrochloride).
  • the pyrrole ring was formed by reacting 3, 3-dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -6-amino-2, 3-dihydro -l, 2-benzisothiazole-1, 1-dioxide with 2, 5-dimethoxytetrahydrofuran in glacial acetic acid at 100 ° C (1 h) in 86% yield.
  • Example 12 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -6-benzoylamido-2, 3-dihydro-l, 2-benzisothiazole-1,1-dioxide (mp: 127 ° C.).
  • Example 13 3, 3-Dimethyl-2- [3- (4-naphth-1-yl-piperazine-1-yl) prop-1-yl] -6-nitro-2, 3-dihydro-1, 2-benzisothiazole-1,1-dioxide (mp: 203 ° C.).
  • Example 14 3,3-Dimethyl-2- [2- (4- (2,3-dimethylphenyl) piperazin-1-yl) eth-l-yl] -2,3-dihydro-1,2 benzisothiazole-l, l-dioxide (mp: 291 ° C., hydrochloride).
  • Example 15 3, 3-Dimethyl-2- [2- (4-indan-4-yl-piperazine-1-yl) eth-1-yl] -2, 3-dihydro-1, 2-benzisothiazole- l, 1-dioxide (mp: 271 ° C, hydrochloride).
  • Example 16 3, 3-Dimethyl-2- [3- (4- (4-chloro-naphth-1-yl) piperazin-1-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 151 ° C.).
  • Example 17 3, 3-Dimethyl-2- [3- (4-pyrimidin-2-yl-piperazine-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 263 ° C, hydrochloride).
  • Example 18 3,3-Dimethyl-2- [2- (4- (4-methoxyphenyl) piperazin-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzoiso- thiazole-1,1-dioxide (mp: 207 ° C, hydrochloride).
  • Example 19 3,3-Dimethyl-2- [3- (4- (2-methoxyphenyl) piperazin-1-yl) -2-hydroxy-prop-l-yl] -2, 3-dihydro -l, 2-benzisothiazole-l, 1-dioxide (mp: 160 ° C).
  • Example 20 3,3-diethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 179 ° C).
  • Example 21 3,3-Dimethyl-2- [3- (4- (2,5-dimethylphenyl) piperazin-1-yl) prop-1-yl] -2,3-dihydro-1,2 benzisothiazole-1,1-dioxide (mp: 218 ° C., hydrochloride).
  • Example 22 3,3-Dimethyl-2- [2- (4- (2-cyano-phenyl) -piperazin-1-yl) -eth-1-yl] -2, 3-dihydro-1,2-benziso - thiazole-1,1-dioxide (mp: 228 ° C, hydrochloride).
  • One use according to the invention also relates to neuroprotection.
  • the use according to the invention can take place in the usual way orally or parenterally, intravenously or intramuscularly.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
  • the medicines can be used in common galenical forms of application in solid or liquid form, for example as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et. Al: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.
  • central nervous disorders such as seasonal mood disorders and dysthymia.
  • anxiety such as generalized anxiety, panic attacks, sociophobia, obsessive-compulsive disorders and post-traumatic stress symptoms, memory disorders including dementia, amnesias and age-related memory loss as well as psychogenic eating disorders such as anorexia nervosa and bulimia nervosa.
  • A represents branched or unbranched (C ⁇ _ 10 ) alkylene or straight-chain or branched (C 2 - ⁇ o) alkylene which comprises at least one group Z which is selected from 0, S, NRs, cyclopropyl, C0 2 , CHOH , a double or a triple bond,
  • B represents 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine or the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and
  • Ar for phenyl which is branched or unbranched by (C ⁇ _ 5 ) alkyl, O- (Ci_ 6 ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 2 2 , C0 2 R 2 , cyano or substituted phenyl, tetralin, indane, more highly condensed aromatics such as naphthalene, which is optionally substituted by (C ⁇ ) alkyl or 0 (C ⁇ _- ⁇ ) alkyl, anthracene or 5- or 6-membered aromatic heterocycles having 1 to 2 heteroatoms, the are independently selected from O and N, which can also be fused with other aromatic radicals,
  • R ⁇ R 2 independently of one another are -CC 6 alkyl
  • R 3 , R 4 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, OH, O- (C ⁇ - 6 ) alkyl branched or unbranched, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0R 7 , nitro, cyano, pyrrole, for a phenylalkyl C 1 -C 4 radical, which in turn is aromatic on F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy, amino , Cyano or nitro may be substituted, R 5 , R 6 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, COPh, C0 2 tBu, CO- (C 1 -. 4 ) alkyl or together for a 5- or 6-membered ring which optionally contains a second N (for example piperazine),
  • R 7 represents hydrogen and (C ⁇ _ 6 ) alkyl branched or unbranched
  • R 8 represents hydrogen and C 1 -C 4 alkyl
  • R 9 for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, CO- (C 1 -) alkyl, C0 2 tBu, CO-aryl and a phenylalkyl -C-C 4 radical, which in turn on the aromatic through F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro can be substituted,
  • One use according to the invention also relates to neuroprotection.
  • the preparation as a medicament is carried out with a compound of the formula I or its pharmacologically acceptable acid addition salt as an active ingredient, together with customary carrier and diluent.
  • a compound of the formula I or its pharmacologically acceptable acid addition salt as an active ingredient, together with customary carrier and diluent.
  • the use according to the invention can take place in the usual way orally or parenterally, intravenously or intramuscularly.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
  • the drugs can be used in common galenical forms of administration, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et. Al: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés de la formule (I) dans laquelle les substituants ont la signification mentionnée dans la description, ainsi que leurs sels avec des acides pharmacologiquement tolérables pour préparer des médicaments pour assurer la prophylaxie et le traitement de l'ischémie cérébrale et des accidents cérébrovasculaires.
PCT/EP1999/010275 1999-01-11 1999-12-22 Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale WO2000041697A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA01006966A MXPA01006966A (es) 1999-01-11 1999-12-22 Uso de compuestos de la formula i para la profilaxis y terapia de la isquemia cerebral.
JP2000593308A JP2002534467A (ja) 1999-01-11 1999-12-22 大脳虚血の予防および治療のための２−置換された１，２−ベンゾイソチアゾール誘導体および３−置換されたテトラヒドロピリドピリミジノン誘導体の使用
CA002359390A CA2359390A1 (fr) 1999-01-11 1999-12-22 Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale
AU22851/00A AU2285100A (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
BR9916888-0A BR9916888A (pt) 1999-01-11 1999-12-22 Uso de compostos e seus sais com ácidosfarmacologicamente aceitáveis
IL14414599A IL144145A0 (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
SK968-2001A SK9682001A3 (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
KR1020017008690A KR20010101440A (ko) 1999-01-11 1999-12-22 대뇌 허혈의 예방 및 치료를 위한 2-치환된1,2-벤즈이소티아졸 유도체 및 3-치환된테트라히드로피리도피리미디논 유도체의 용도
EP99966990A EP1140099A1 (fr) 1999-01-11 1999-12-22 Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale
PL99348916A PL348916A1 (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
BG105688A BG105688A (en) 1999-01-11 2001-07-10 Utilization of compounds for the prophylaxis and therapy of cerbral ischaemia
NO20013408A NO20013408L (no) 1999-01-11 2001-07-10 Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
DE19900544.3 1999-01-11

Publications (1)

Publication Number Publication Date
WO2000041697A1 true WO2000041697A1 (fr) 2000-07-20

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/010275 WO2000041697A1 (fr) 1999-01-11 1999-12-22 Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale

Country Status (19)

Country Link
EP (1) EP1140099A1 (fr)
JP (1) JP2002534467A (fr)
KR (1) KR20010101440A (fr)
CN (1) CN1333685A (fr)
AR (1) AR029741A1 (fr)
AU (1) AU2285100A (fr)
BG (1) BG105688A (fr)
BR (1) BR9916888A (fr)
CA (1) CA2359390A1 (fr)
DE (1) DE19900544A1 (fr)
HU (1) HUP0200520A3 (fr)
IL (1) IL144145A0 (fr)
MX (1) MXPA01006966A (fr)
NO (1) NO20013408L (fr)
PL (1) PL348916A1 (fr)
SK (1) SK9682001A3 (fr)
TR (1) TR200102009T2 (fr)
WO (1) WO2000041697A1 (fr)
ZA (1) ZA200105473B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038752A3 (fr) * 2007-09-20 2009-07-09 Cortex Pharma Inc 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques
EP3233826A1 (fr) * 2014-12-17 2017-10-25 Aziende Chimiche Riunite Angelini Francesco A.C.R. Nouveaux composés antibactériens

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041210A2 (fr) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Agents antibacteriens
US7691879B2 (en) * 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
EP0360077A2 (fr) * 1988-09-20 1990-03-28 Troponwerke GmbH & Co. KG Utilisation des antagonistes de la sérotonine dans le traitement de l'apoplexie cérébrale
JPH0454181A (ja) * 1990-06-22 1992-02-21 Mitsui Petrochem Ind Ltd 新規な複素環式化合物及び医薬組成物
WO1999020616A1 (fr) * 1997-10-22 1999-04-29 Basf Aktiengesellschaft Derives de 1,2-benzisothiazol 2-substitues, leur preparation et leur utilisation comme antagonistes de la serotonine (5-ht1a, 5-ht1b et 5-ht1d)
WO1999021857A1 (fr) * 1997-10-24 1999-05-06 Basf Aktiengesellschaft Derives de tetrahydropyridopyrimidinone substitues en position 3, leur production et leur utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
EP0360077A2 (fr) * 1988-09-20 1990-03-28 Troponwerke GmbH & Co. KG Utilisation des antagonistes de la sérotonine dans le traitement de l'apoplexie cérébrale
JPH0454181A (ja) * 1990-06-22 1992-02-21 Mitsui Petrochem Ind Ltd 新規な複素環式化合物及び医薬組成物
WO1999020616A1 (fr) * 1997-10-22 1999-04-29 Basf Aktiengesellschaft Derives de 1,2-benzisothiazol 2-substitues, leur preparation et leur utilisation comme antagonistes de la serotonine (5-ht1a, 5-ht1b et 5-ht1d)
WO1999021857A1 (fr) * 1997-10-24 1999-05-06 Basf Aktiengesellschaft Derives de tetrahydropyridopyrimidinone substitues en position 3, leur production et leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIELENBERG, G. W. ET AL: "5-Hydroxytryptamine1A agonists. A new therapeutic principle for stroke treatment", STROKE (DALLAS) (1990), 21(12, SUPPL.), IV-161-IV-163, XP000911082 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IMUDA, JUNICHI ET AL: "Preparation of heterocyclic compounds as psychotropic agents", XP002139262, retrieved from STN Database accession no. 117:48598 *
F CLAUDI ET AL: "3-[2-(4-Fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro-4(3H)- quinazolinones: serotonin 5-HT2A receptor antagonists endowed with potent central action", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA,FR,EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 32, no. 7/08, 1 January 1997 (1997-01-01), pages 651 - 659, XP002095654, ISSN: 0223-5234 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038752A3 (fr) * 2007-09-20 2009-07-09 Cortex Pharma Inc 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques
EP3233826A1 (fr) * 2014-12-17 2017-10-25 Aziende Chimiche Riunite Angelini Francesco A.C.R. Nouveaux composés antibactériens
US10369130B2 (en) 2014-12-17 2019-08-06 AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Antibacterial compounds

Also Published As

Publication number Publication date
BR9916888A (pt) 2001-11-20
CA2359390A1 (fr) 2000-07-20
MXPA01006966A (es) 2002-04-10
TR200102009T2 (tr) 2002-01-21
NO20013408D0 (no) 2001-07-10
PL348916A1 (en) 2002-06-17
HUP0200520A3 (en) 2003-04-28
DE19900544A1 (de) 2000-07-13
AR029741A1 (es) 2003-07-16
EP1140099A1 (fr) 2001-10-10
JP2002534467A (ja) 2002-10-15
AU2285100A (en) 2000-08-01
SK9682001A3 (en) 2002-03-05
CN1333685A (zh) 2002-01-30
KR20010101440A (ko) 2001-11-14
BG105688A (en) 2002-02-28
IL144145A0 (en) 2002-05-23
HUP0200520A2 (hu) 2002-07-29
NO20013408L (no) 2001-08-21
ZA200105473B (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE60315516T2 (de) Pyridazinon-derivate als cdk2-hemmer
JP2941945B2 (ja) 新規な４−アリールピペラジン類および４−アリールピペリジン類
DE3248160C2 (de) 2-[4-[(4,4-Dialkyl-2,6-piperidindion-1-yl)-butyl]-1-piperazinyl]pyrimidine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten
EP0877744B1 (fr) Composes aza- et diazacycloheptane et -cyclo-octane substitues et leur utilisation
EP1025100B1 (fr) Derives de tetrahydropyridopyrimidinone substitues en position 3, leur production et leur utilisation
DE2415082A1 (de) Disubstituierte piperazine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE19636769A1 (de) 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
DE60004671T2 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
EP0101574A1 (fr) 1-aminoalkyl-1,2,3,4-tétrahydro-beta-carbolines, leur préparation et leur utilisation comme médicaments
EP1140096A1 (fr) Utilisation de derives de pyrimidine pour assurer la prophylaxie et la therapie de l'ischemie cerebrale
AT391698B (de) Verfahren zur herstellung neuer zyklischer imid- derivate von 2-(4-butylpiperazin-1-yl)-pyridinen
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
EP1140099A1 (fr) Utilisation de derives de 1,2-benzisothiazol 2-substitues et de derives de tetrahydropyridopyrimidinone 3-substitues pour assurer la prophylaxie et le traitement de l'ischemie cerebrale
DE4325900A1 (de) Trisubstituierte Pyrimido [5,4-d] pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1034170A1 (fr) Derives de 1,2-benzisothiazol 2-substitues, leur preparation et leur utilisation comme antagonistes de la serotonine (5-ht1a, 5-ht1b et 5-ht1d)
EP2029580B1 (fr) Nouveaux dérivés d'indole-pyrrole pour le traitement de maladies prolifératives et inflammatoires
EP0139993A2 (fr) Dérivés de quinazoline, procédé pour leur préparation et médicaments contenant ces composés
EP1023296A1 (fr) Derives de pyrido 3',4':4,5]thieno 2,3-d]pyrimidine 3-substitues, leur preparation et leur utilisation
EP0580644B1 (fr) Derives 1,3,4-trisubstitues de la piperidine, preparation et utilisation desdits derives
DE3529872A1 (de) Neue tetraoxoverbindungen
EP0731801B1 (fr) Aminoalkylaminopyridines substituees
WO2011151701A1 (fr) Dérivés de 6 - méthyl - 4 - phényl - 5 - (phényl ou cycloalkyl) carbamoyl - 1,2,3, 4 - tétrahydropyrimidin- 2 - one utilisés en tant qu'agents antituberculeux
CZ20001436A3 (cs) Disubstituované deriváty 1,2-benzisotiazolu a jejich použití
MXPA00002601A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
MXPA00003136A (en) 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99815452.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999966990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 512756

Country of ref document: NZ

Ref document number: 200105473

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 144145

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 9682001

Country of ref document: SK

Ref document number: IN/PCT/2001/953/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006966

Country of ref document: MX

Ref document number: PV2001-2484

Country of ref document: CZ

ENP Entry into the national phase

Country of ref document: CA

Ref document number: 2359390

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1999 105688

Country of ref document: BG

Kind code of ref document: A

Ref document number: 2000 593308

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 22851/00

Country of ref document: AU

Ref document number: 1020017008690

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001/02009

Country of ref document: TR

Ref document number: 09889165

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P20010592A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1999966990

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017008690

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2484

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999966990

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017008690

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-2484

Country of ref document: CZ